Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients

Table 1

Sociodemographic and clinical characteristics of the study population.

	Olanzapine-treated group ()	First episode drug-naïve group ()	Healthy control ()	^#	Multicomparison
Age (years)				0.336	—
Gender (F/M)	55/46	28/21	40/31	0.974	—
Body weight (kg)				<0.001	, H
BMI				<0.001	, H
Physical activity index^a				0.893	—
Smoking (Y/N)	27/74	5/44	11/60	0.395	—
Drinking (Y/N)	17/84	6/43	3/68	0.232	—
Dosage (mg/d)^b		—	—	—	—
Duration of olanzapine use (year)		—	—	—	—
Duration of illness (year)				<0.001
PANSS				0.021

^aPhysical activity . ^bOlanzapine medication dosages were transformed to chlorpromazine equivalent dosages. ^#Comparison of sociodemographic and clinical characteristics among the olanzapine-treated, first episode drug-naïve, and healthy control groups.